Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compugen (CGEN) Total Current Liabilities (2016 - 2025)

Compugen's Total Current Liabilities history spans 17 years, with the latest figure at $22.6 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 11.95% to $22.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.6 million, a 11.95% increase, with the full-year FY2025 number at $22.6 million, up 11.95% from a year prior.
  • Total Current Liabilities hit $22.6 million in Q4 2025 for Compugen, up from $20.3 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for CGEN hit a ceiling of $27.8 million in Q3 2024 and a floor of $10.4 million in Q3 2023.
  • Historically, Total Current Liabilities has averaged $17.6 million across 5 years, with a median of $16.4 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: crashed 31.74% in 2023 and later surged 167.55% in 2024.
  • Tracing CGEN's Total Current Liabilities over 5 years: stood at $17.1 million in 2021, then plummeted by 30.28% to $11.9 million in 2022, then skyrocketed by 120.37% to $26.3 million in 2023, then fell by 23.25% to $20.2 million in 2024, then rose by 11.95% to $22.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for CGEN at $22.6 million in Q4 2025, $20.3 million in Q3 2025, and $20.6 million in Q2 2025.